Glomerulosclerosis, Focal Segmental
A clinicopathological syndrome or diagnostic term for a type of glomerular injury that has multiple causes, primary or secondary. Clinical features include PROTEINURIA, reduced GLOMERULAR FILTRATION RATE, and EDEMA. Kidney biopsy initially indicates focal segmental glomerular consolidation (hyalinosis) or scarring which can progress to globally sclerotic glomeruli leading to eventual KIDNEY FAILURE.
Drugs by status
Phase 4 trials (5)
Phase 3 trials (11)
Phase 2 trials (31)
- metformin
- ccx-140
- bardoxolone
- losmapimod
- n-acetylmannosamine
- pirfenidone
- adalimumab
- atorvastatin
- atacicept
- Rilzabrutinib
- sirolimus
- cyclophosphamide
- abatacept
- Anti-thymocyte Globulin (Rabbit)
- voclosporin
- retinoids
- losartan
- fludarabine
- blood plasma
- atrasentan hydrochloride
- sodium chloride
- melphalan
- lisinopril
- gfb-887
- Galactose
- propagermanium
- Inaxaplin
- vb119
- r3r01
- frexalimab
- +1 more
Phase 1 trials (7)
Other trials (3)
Organizations
Organization Involved with Phase 4 Indications (6)
Organization Involved with Phase 3 Indications (10)
Organization Involved with Phase 2 Indications (26)
- Bristol-Myers Squibb
- Vertex
- Astellas
- Genentech
- Genzyme
- Pfizer
- Aurinia Pharmaceuticals Inc.
- ChemoCentryx
- GlaxoSmithKline
- Kyowa Hakko Kirin
- Reata Pharmaceuticals, Inc.
- Complexa, Inc.
- National Institutes of Health (NIH)
- Indiana University
- New York University
- University of Michigan
- Mayo Clinic
- Department of Defense
- Medpace, Inc.
- Rush University
- NephCure Accelerating Cures Institute
- IQVIA
- Dimerix Bioscience Pty Ltd
- Arkana Laboratories
- MicroConstants
- Goldfinch Bio, Inc.
Organization Involved with Phase 1 Indications (10)
Organization Involved with Other Experimental Indications (4)